The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Keflex 250 mg Hard Capsules

Flynn Pharma LimitedPA1226/002/001

Main Information

Trade NameKeflex 250 mg Hard Capsules
Active SubstancesCefalexin Anhydrous
Dosage FormCapsule, hard
Licence HolderFlynn Pharma Limited
Licence NumberPA1226/002/001

Group Information

ATC CodeJ01DB First-generation cephalosporins
J01DB01 cefalexin


License statusAuthorised
Licence Issued14/04/1977
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
« Back